ArticleJournal of neuroinflammation2020
Perturbation of gut microbiota decreases susceptibility but does not modulate ongoing autoimmune neurological disease.
Article in Journal of neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment.Cells · 2025Article
- Gut microbiota in multiple sclerosis and animal models.The FEBS journal · 2025Review
- Life history of a brain autoreactive T cell: From thymus through intestine to blood-brain barrier and brain lesion.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Review
- Review
- The Gut-Brain Axis in Autoimmune Diseases: Emerging Insights and Therapeutic Implications.Cureus · 2023Review
- Gut microbiome-modulated dietary strategies in EAE and multiple sclerosis.Frontiers in nutrition · 2023Review
- Novel Role of Ghrelin Receptor in Gut Dysbiosis and Experimental Colitis in Aging.International journal of molecular sciences · 2022Article
- Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis.Frontiers in molecular neuroscience · 2022Review
- Complement component 3 from astrocytes mediates retinal ganglion cell loss during neuroinflammation.Acta neuropathologica · 2021Article
- Sepsis and multiple sclerosis: Causative links and outcomes.Immunology letters · 2021Review
- Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- The Nerves to Conduct a Multiple Sclerosis Crime Investigation.International journal of molecular sciences · 2021Review
- ILC3, a Central Innate Immune Component of the Gut-Brain Axis in Multiple Sclerosis.Frontiers in immunology · 2021Review
- The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?Frontiers in immunology · 2021Review
- [Microbiota and multiple sclerosis].Der Nervenarzt · 2020Review
- Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?International journal of molecular sciences · 2020Review
- The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology.Frontiers in immunology · 2020Review
- Intestinal Dysbiosis and Tryptophan Metabolism in Autoimmunity.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
The gut microbiota regulates the host immune and nervous systems and plays an important role in the pathogenesis of autoimmune neurological disease multiple sclerosis (MS). There are considerable efforts currently being undertaken to develop therapies for MS based on the modulation of microbiota. Evidence from experimental models suggests that the manipulation of microbiota through diet or antibiotics prior to the disease development limits disease susceptibility. However, it is currently unclear if microbiota manipulation therapies would also have an impact on ongoing neurological disease. Here, we examined the effect of antibiotic-based microbiota modulation in spontaneous experimental autoimmune encephalomyelitis (EAE) mouse models of MS before and after the onset of autoimmune disease. Prophylactic antibiotic treatment led to a significant reduction of susceptibility to spontaneous EAE. In contrast, antibiotic treatment after the onset of spontaneous EAE did not show a significant amelioration. These results reveal that the perturbation of gut bacteria alters disease susceptibility but has minimal impact on the ongoing neurological disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.